ArticleCytotechnology2025
Expression and localization of lysosomal-associated membrane protein 1- and perforin-based hybrid molecules in the murine cytotoxic T cell line CTLL-2.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytotoxic T lymphocytes (CTL) and natural killer cells harbor lytic granules as secretory lysosomes. Lytic granules contain perforin as a soluble protein that forms pores and is essential for target cell lysis. Lysosomal-associated membrane protein 1 (LAMP1) is a single transmembrane protein that is enriched in lysosomes and is also present in lytic granules. In this study, to investigate the feasibility of membrane-integral markers for lytic granules, LAMP1- and perforin-based hybrid molecules were constructed and their expression and localization were examined in the murine cytotoxic T-cell line CTLL-2. Stable CTLL-2 transfectants were established by nucleofection using linearized vectors encoding human LAMP1 (1-417) fused to enhanced green fluorescent protein (EGFP) and FLAG (LAMP1-EGFP-FLAG) and human perforin (1-555) fused to human LAMP1 (325-417), EGFP, and FLAG (Perforin-LAMP1-EGFP-FLAG). Confocal microscopy showed that LysoTracker Red colocalized with LAMP1-EGFP-FLAG and Perforin-LAMP1-EGFP-FLAG, and Perforin-LAMP1-EGFP-FLAG showed a broader cytoplasmic distribution than LAMP1-EGFP-FLAG. A Percoll density gradient centrifugation analysis revealed that LAMP1-EGFP-FLAG and Perforin-LAMP1-EGFP-FLAG were distributed in fractions associated with the endogenous expression of perforin and LAMP1. The effects of glycosylation inhibitors on the expression and intracellular transport of LAMP1-EGFP-FLAG were also investigated. Concanamycin A, an inhibitor of vacuolar-type H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.